{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-014191","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.919324+00:00","generated_at":"2026-06-06T03:41:11.771202+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Candel receives FDA Fast Track Designation for CAN-3110 in recurrent high-grade glioma","bullets":["FDA granted Fast Track Designation for CAN-3110, an HSV-1 oncolytic viral immunotherapy for recurrent HGG to improve overall survival.","Phase 1b data published in Nature (Oct 2023) showed median overall survival ~12 months after single injection vs historical <6-9 months.","Positive HSV-1 serology associated with mOS of 14 months; T-cell repertoire expansion and local/systemic antitumoral response observed.","Ongoing phase 1b trial evaluating multiple injections of CAN-3110; additional data expected in H2 2024.","Fast Track designation may accelerate development and regulatory review for this therapy-resistant brain cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-014191","json":"https://secwatch.observer/filing/0000950170-24-014191.json","markdown":"https://secwatch.observer/filing/0000950170-24-014191.md","text":"https://secwatch.observer/filing/0000950170-24-014191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024014191/0000950170-24-014191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024014191/cadl-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:41:11.771202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}